Associated Papers
Predictor Role of VKORC1 rs9923231, CYP4F2 rs2108622, and GGCX rs11676382 Polymorphisms of 5 Years Mortality of Patients with Acute Ischemic Stroke.
Iluţ S et al.
Medicina (kaunas, Lithuania), 2025
Association between gene polymorphisms and initial warfarin therapy in patients after heart valve surgery.
Liu Z et al.
Pharmacological Reports : Pr, 2024
Coronary artery disease, its associations with ocular, genetic and blood lipid parameters.
Matulevičiūtė I et al.
Eye (london, England), 2024
Association among VKORC1 rs9923231, CYP4F2 rs2108622, GGCX rs11676382 polymorphisms and acute ischemic stroke.
Iluţ S et al.
Medicine, 2023
Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.
Hirata TDC et al.
Molecular Diagnosis & Therapy, 2021
ABCA1 rs1883025 and CYP4F2 rs2108622 Gene Polymorphism Association with Age-Related Macular Degeneration and Anti-VEGF Treatment.
Mockute R et al.
Medicina (kaunas, Lithuania), 2021
[Pharmacogenomics of vitamin K antagonists].
Guzmán N et al.
Revista Medica De Chile, 2020
CYP4F2 and VKORC1 Polymorphisms Amplify the Risk of Carotid Plaque Formation.
Vesa SC et al.
Genes, 2020
Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.
Danese E et al.
Clinical Pharmacology and Therapeutics, 2019
The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
Wattanachai N et al.
European Journal of Clinical Pharmacology, 2017
Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients.
Khosropanah S et al.
Iranian Journal of Pharmaceutical Research : Ijpr, 2017
A model analysis for dose-response relationship of warfarin in Japanese children: An introduction of the SIZE parameter.
Nakamura S et al.
Drug Metabolism and Pharmacokinetics, 2016
CYP4F2 (rs2108622) Gene Polymorphism Association with Age-Related Macular Degeneration.
Sakiene R et al.
Advances in Medicine, 2016
Pharmacogenetics of coumarin anticoagulants in Brazilians.
Suarez-Kurtz G et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.
Kim KA et al.
Molecular Biology Reports, 2014
Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients.
Tomita H et al.
Thrombosis Research, 2013
Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T et al.
European Journal of Clinical Pharmacology, 2013
Pharmacogenomics of warfarin in populations of African descent.
Suarez-Kurtz G et al.
British Journal of Clinical Pharmacology, 2013
Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
Ma C et al.
International Journal of Hematology, 2012
Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
Danese E et al.
Clinical Pharmacology and Therapeutics, 2012
Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in Chinese valve replacement patients.
Li JH et al.
Journal of Cardiothoracic Surgery, 2012
CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
Nakamura K et al.
Journal of Clinical Pharmacy and Therapeutics, 2012
Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.
Lacut K et al.
British Journal of Clinical Pharmacology, 2012
Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.
Botton MR et al.
British Journal of Clinical Pharmacology, 2011
Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.
Gao L et al.
Chinese Medical Journal, 2011
Pharmacogenetic aspects of coumarinic oral anticoagulant therapies.
Rathore SS et al.
Indian Journal of Clinical Biochemistry : Ijcb, 2011
Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
Aomori T et al.
Die Pharmazie, 2011
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction.
Kringen MK et al.
Journal of Biomedicine & Biotechnology, 2011
A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
Wells PS et al.
Thrombosis Research, 2010